Substance / Medication

Cefpodoxime

Overview

Active Ingredient
cefpodoxime
RxNorm CUI
20489

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

37 trials linked to this intervention

37
Total Trials
7
Recruiting
10
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Clinical pharmacokinetics of cefpodoxime: a systematic review.
Farooq Ayesha, Zamir Ammara, Imran Imran et al. · Expert Opin Drug Metab Toxicol · 2024
PMID: 39120118Meta-Analysis
The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs.
Brown S A, Boucher J F, Hubbard V L et al. · J Vet Pharmacol Ther · 2007
PMID: 17610405RCT
Cefpodoxime proxetil compared with cefixime for treatment of typhoid fever in children.
Shakur Md Salim, Arzuman Selina Akhter Laila, Hossain Jesmin et al. · Indian Pediatr · 2007
PMID: 18057480RCT
Ceftriaxone Versus Cefazolin Susceptibility as a Surrogate Marker for Cefpodoxime Susceptibility in Enterobacterales.
Lambert Kaitlyn V, Demkowicz Ryan, Murray Amanda et al. · Open Forum Infect Dis · 2024
PMID: 39006314TrialFull text (PMC)
Levofloxacin versus Cefpodoxime for Antibacterial Prophylaxis in Allogeneic Stem Cell Transplantation.
Doan Vi P, Yeh Jason C, Gulbis Alison M et al. · Biol Blood Marrow Transplant · 2019
PMID: 31002991Trial
Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors.
McGregor Lisa M, Stewart Clinton F, Crews Kristine R et al. · Pediatr Blood Cancer · 2012
PMID: 21509928TrialFull text (PMC)
Tissue penetration of cefpodoxime and cefixime in healthy subjects.
Liu Ping, Müller Markus, Grant Maria et al. · J Clin Pharmacol · 2005
PMID: 15831780Trial
Comparative evaluation of cefpodoxime versus cefixime in children with lower respiratory tract infections.
Sengupta Jayati, Mondal A K, Jain Piyush et al. · Indian J Pediatr · 2004
PMID: 15226561Trial
Cefpodoxime-proxetil versus trimethoprim-sulfamethoxazole for short-term therapy of uncomplicated acute cystitis in women.
Kavatha Demetra, Giamarellou Helen, Alexiou Zoe et al. · Antimicrob Agents Chemother · 2003
PMID: 12604518TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Cefpodoxime (substance)
SNOMED CT
387534007
UMLS CUI
C0055011
RxNorm CUI
20489

Clinical Data

This intervention maps to 13 entities in the Ltrl knowledge graph.

13
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
37
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.